Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

Abstract

NCT01280201.

WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine

“…Sunitinib is an approved therapy in progressive pancreatic NET based on prolongation of PFS by 6 months compared with placebo (median PFS 11.4 months with sunitinib vs 5.5 months on placebo; Raymond et al 2011). Circulating cytokines (interleukin-8, soluble VEGFR-3 and stromal cell-derived factor-1α) and circulating tumor cells have been associated with outcome to sunitinib and pazopanib therapy (Ebos et al 2007, Grande et al 2015, Zurita et al 2015, but none of these markers is validated or established in clinical practice. There is no definite evidence of efficacy of tyrosine kinase inhibitors in nonpancreatic NET yet, although phase II trials indicate some efficacy of novel tyrosine kinase inhibitors (pazopanib, axitinib) , Strosberg et al 2016.…”

Nowotwory neuroendokrynne trzustki — zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)

“…At the moment, there is insufficient evidence supporting the use of other targeted therapies, such as bevacizumab, sorafenib, pazopanib, or axitinib, in the treatment of pancreatic NENs [222][223][224].…”

Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?

“…Pazopanib has been investigated in several single-arm phase II studies in pancreatic and extrapancreatic NETs, with PFS ranging from 9.1 to 14.4 months (60)(61)(62). A placebo-controlled randomized phase II clinical trial, A021202, is ongoing to evaluate the efficacy of pazopanib in progressive well-differentiated non-pancreatic NETs (NCT01841736).…”

“…Notably, SDF-1α, or CXCL12, is a chemokine that binds its receptor CXCR4 to promote vascular endothelial cell migration during neovascularization and also promotes leukocyte chemotaxis (65). In another phase II study of pazopanib in patients with pancreatic or non-pancreatic well-differentiated NETs, there were non-significant trends toward improved PFS in patients with no baseline circulating tumor cells, lower soluble-VEGFR2 levels, absence of the VEGFR3 rs307821 (R1324L) polymorphism, a n d a b s e n c e o f t h e V E G F R 3 r s 3 0 7 8 2 6 ( T 4 9 4 A ) polymorphism (61). The results were not significant, though could be underpowered.…”